Neurocrine Biosciences appoints Samir Siddhanti chief business officer

The executive, who joined in 2017 and most recently led business development, also joins the company’s executive Management Committee after helping steer transactions including the $2.9 billion Soleno Therapeutics acquisition.

Summary

verifying reliability

Terms & Concepts

No specialized terms available for this topic.